WHO's 2026-02-13 prequalification of an additional novel oral polio vaccine type 2 from Biological E strengthens global supply against cVDPV2 outbreaks, as wild polio cases and vaccine-derived cases decline but persist in a few regions.([who.int](https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine?utm_source=openai)) This forecast assesses eradication prospects over 1-50 years.
Verdict: Additional nOPV2 prequalification meaningfully reduces supply risk for outbreak response, especially as Biological E can now produce bulk and finished vaccine in-house (WHO, 2026-02-13; Biological E reporting, 2026-02-13).([who.int](https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine?utm_source=openai)) Combined with a recent US$1.9 billion pledge and falling wild-polio and cVDPV2 case counts, the world is closer than ever to eradication but not yet guaranteed success (GPEI-related announcements, 2025-12-08; WHO IHR Committee, 2025-11-11).([adgm.com](https://www.adgm.com/media/announcements/global-leaders-pledge-us%24-1.9-billion-in-abu-dhabi-to-end-polio-and-protect-children-worldwide?utm_source=openai)) Persistent conflict, insecurity and misinformation in a few countries remain the main obstacles over the next decade (AP reporting on Pakistan, 2025-12-15).([apnews.com](https://apnews.com/article/f2c57078a42d81e05b2802181b53469c?utm_source=openai))
Security and access improve in key remaining reservoirs, allowing consistently high-quality campaigns using the expanded nOPV2 supply. Wild poliovirus transmission is interrupted globally in the early 2030s and cVDPV2 outbreaks fall to sporadic, quickly controlled events. A carefully sequenced OPV withdrawal avoids major new vaccine-derived outbreaks, enabling eventual certification of eradication for all poliovirus types.
Wild poliovirus is eliminated from Pakistan and Afghanistan within the next decade, supported by better micro-planning, local negotiations and strong funding.([who.int](https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine?utm_source=openai)) However, low-level cVDPV2 transmission continues to flare in fragile settings, necessitating periodic reactive nOPV2 campaigns into the 2040s. Global certification for wild polio occurs earlier than for vaccine-derived strains, leaving a long tail of risk management.
Conflict, political instability and targeted violence against vaccinators intensify in several endemic or high-risk regions.([apnews.com](https://apnews.com/article/f2c57078a42d81e05b2802181b53469c?utm_source=openai)) Campaign quality deteriorates and large pockets of under-immunised children persist, sustaining both wild poliovirus and cVDPV2 circulation. Donor fatigue and competing global crises erode funding, forcing a retrenchment to damage-limitation rather than eradication.
A rare but high-profile adverse event or misinformation wave linked, fairly or unfairly, to nOPV2 dramatically undermines trust in oral vaccines. Regulators respond with new safeguards that temporarily slow campaigns and require reformulated products. Alternatively, a technological breakthrough in thermostable, single-dose IPV or mucosal vaccines transforms the eradication toolkit and accelerates the endgame.
Developments: With WHO prequalification, Biological E scales integrated production of nOPV2, reducing bottlenecks and lead times for outbreak response campaigns.([who.int](https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine?utm_source=openai)) Additional stocks allow more simultaneous or follow-up rounds in regions facing cVDPV2, tightening control. Wild poliovirus cases remain concentrated in a few districts in Pakistan and Afghanistan, with ongoing synchronised campaigns across their border.([who.int](https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine?utm_source=openai))
Risks: Security incidents against vaccinators or health facilities can abruptly halt campaigns in high-risk areas. Underfunded routine immunisation programs may leave new cohorts susceptible even as campaigns focus on hotspots. Overconfidence in nOPV2's genetic stability could reduce vigilance for rare reversion events documented by surveillance.
Outlook: In the first year, operational capacity to respond improves faster than on-the-ground access. The main risk is local backsliding in fragile settings, not global strategy failure. Maintaining front-line worker safety and community trust is as important as vaccine supply.
Developments: If campaigns succeed, both wild-polio and cVDPV2 case numbers fall further, continuing the downward multi-year trend.([who.int](https://www.who.int/news/item/28-07-2025-statement-of-the-forty-second-meeting-of-the-polio-ihr-emergency-committee?utm_source=openai)) Donors and governments begin debating timelines for transitioning from emergency campaigns to stronger routine immunisation and IPV-focused strategies. Technical bodies refine guidance on when and how to switch or withdraw specific OPV types without seeding new outbreaks.
Risks: Premature scaling back of campaigns in areas with weak surveillance could allow silent transmission to continue. Political interest may wane as case numbers drop, complicating efforts to sustain high coverage and surveillance sensitivity. Disagreements over OPV withdrawal timing among partners could fragment implementation and confuse national programmes.
Outlook: By year two, success will be visible in aggregate numbers but fragile in specific locales. Strategic decisions about the balance between campaigns, routine services and OPV withdrawal will shape the next decade. The system must avoid mistaking early victories for final eradication.
Developments: Environmental and genomic surveillance become increasingly important as acute flaccid paralysis cases decline, providing early warning of residual transmission.([who.int](https://www.who.int/news/item/28-07-2025-statement-of-the-forty-second-meeting-of-the-polio-ihr-emergency-committee?utm_source=openai)) Some countries pilot more integrated surveillance platforms that track multiple pathogens, using polio infrastructure as a backbone. International review bodies conduct intensive certification-style assessments in regions that appear polio-free, probing for blind spots.
Risks: If surveillance quality degrades, especially in insecure or low-resource settings, apparent success may mask ongoing circulation. Integration with broader health surveillance could dilute polio-specific focus and expertise. Detection of a new cVDPV2 emergence associated with nOPV2, even if rare, could trigger precautionary pauses or redesigns.
Outlook: Three years out, the emphasis shifts from raw campaign numbers to the quality of surveillance and verification. The system must demonstrate it can find the last cases, not just reduce most of them. Successful integration with broader health systems can either strengthen or weaken that capacity.
Developments: By around 2031, sustained high-quality campaigns and improved access make global interruption of wild poliovirus transmission plausible, particularly if Pakistan and Afghanistan maintain recent coverage gains.([who.int](https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine?utm_source=openai)) Certification processes begin in some WHO regions, using stringent criteria drawn from prior eradication programmes. Attention increasingly turns to managing residual cVDPV2 risk and planning OPV cessation in stages.
Risks: Last-mile challenges in border areas, informal settlements and conflict zones could delay certification for several years. A major geopolitical crisis or pandemic could divert resources and personnel away from polio at a critical juncture. Communicating the difference between wild-polio elimination and ongoing vaccine-derived risks may prove difficult, risking confusion and resistance.
Outlook: At five years, ending wild polio globally is realistic but not automatic. The remaining risks are concentrated, political and logistical rather than scientific. Clear communication and sustained funding will be decisive for turning near-eradication into certified eradication.
Developments: By the mid-2030s, wild poliovirus is likely certified eradicated worldwide if current trends continue.([who.int](https://www.who.int/news/item/13-02-2026-who-prequalifies-additional-novel-oral-polio-vaccine?utm_source=openai)) However, pockets of cVDPV2 may still emerge in low-coverage areas, requiring rapid, targeted use of nOPV2 or successor vaccines. Many countries have shifted to IPV-based schedules with strengthened routine immunisation and integrated disease surveillance systems.
Risks: As memories of polio fade, vaccine hesitancy and complacency may grow, undermining coverage and opening niches for cVDPV outbreaks. Some governments may underinvest in maintaining IPV and surveillance once wild polio is gone, treating it as a solved problem. The logistical and financial burden of sustaining a global readiness posture for a dwindling threat may test donor patience.
Outlook: At 10 years, polio is no longer a common disease but remains a residual risk that demands vigilance. The main challenge is sustaining political and financial commitment for prevention when visible cases are rare. Successfully balancing cost, readiness and broader health priorities determines whether eradication holds.
Developments: Around the mid-2040s, if both wild and vaccine-derived polioviruses have been eliminated in the wild, attention centres on laboratory containment, vaccine manufacturing controls and guarding against accidental reintroduction. Polio infrastructure and expertise have been substantially redeployed into broader immunisation and surveillance systems, especially for other enteric and respiratory diseases. Historical experience informs governance of other eradication or elimination efforts.
Risks: Lapses in containment or breaches in biosecurity at research or manufacturing facilities could reintroduce poliovirus into under-immunised populations. As new pathogens compete for attention, institutional memory about polio-specific risks may erode. If eradication is not fully achieved, continued low-level transmission could undermine trust in global health promises.
Outlook: At 20 years, a successful endgame turns polio from an active threat into a managed historical risk. The focus will be on preventing rare but consequential failures rather than routine control. How well polio assets were integrated into wider health systems will shape broader pandemic preparedness.
Developments: By the 2070s, polio is either a fully eradicated disease or a tightly contained residual risk, and its campaign infrastructure has long been repurposed. Lessons from nOPV2 design, surveillance and the handling of vaccine-derived risks inform approaches to other live vaccines and novel platforms. The history of polio eradication shapes public expectations about what global health can and cannot deliver for future threats.
Risks: If eradication ultimately failed or was reversed, it could foster deep scepticism about ambitious global health goals. Conversely, if success is remembered only as a simple vaccine story, important nuances about governance, equity and security might be lost. Long-term underinvestment in maintaining containment and archival systems could allow old risks to resurface.
Outlook: At the 50-year horizon, polio's main impact is as a reference case for global cooperation, trust and long-term commitment. A remembered success can strengthen resolve for future eradication or elimination campaigns. A perceived failure or partial success could narrow the ambition of global health efforts.